Characterization of inflammatory biomarkers and candidates for diagnosis of Alzheimer’s disease

Biochip Journal

Volumn 8, Issue 3, 2014, Pages 155-162

  Bagyinszky, Eva ^a   Youn, Young Chul ^b   An, Seong Soo A ^a   Kim, Sang Yun ^c  

^a Gachon University   (South Korea)

^b Chung Ang University College of Medicine   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

Author keywords

Alzheimer s disease; Inflammation; Interferon; Interleukin; Therapy; Tumor necrosis factor

Indexed keywords

ANTIBIOTICS; BIOMARKERS; CELL DEATH; DISEASE CONTROL; GLYCOPROTEINS; INTERFERONS; MACROPHAGES; MOLECULES; NEURODEGENERATIVE DISEASES; PATHOLOGY; TUMORS;

ALZHEIMER; INFLAMMATION; INTERLEUKIN; THERAPY; TUMOR NECROSIS FACTORS;

DIAGNOSIS;

ALPHA INTERFERON; BETA INTERFERON; BIOLOGICAL MARKER; GAMMA INTERFERON; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 16; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 33; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ALZHEIMER DISEASE; APOPTOSIS; COGNITION; DEMENTIA; DISEASE ASSOCIATION; DISEASE COURSE; DNA POLYMORPHISM; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; MACROPHAGE; MEMORY DISORDER; MONOCYTE; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW;

EID: 84911958534     PISSN: 19760280     EISSN: 20927843     Source Type: Journal    
DOI: 10.1007/s13206-014-8301-1     Document Type: Review

References (50)

1. Frank R.A. et al. Biological markers for therapeutic trials in Alzheimer’s disease: Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer’s disease. Neurobiol. Aging24, 521–536 (2003).
2. Casoli T. et al. Peripheral inflammatory biomarkers of Alzheimer’s disease: the role of platelets. Biogerontology11, 627–633 (2011).
3. Mrak R.E. Neuropathology and the neuroinflammation idea. J. Alzhemers. Dis.18, 473–481 (2009).
4. McNaull B.B., Todd S., McGuinness B. & Passmore A.P. Inflammation and anti-inflammatory strategies for Alzheimer’s disease — a mini-review. Gerontology56, 3–14 (2010).
5. Elenkov I.J., Wilder R.L., Chrousos G.P. & Vizi S. The sympathetic nerve - an integrative interface between two supersystems: the brain and the immnune system. Pharmacol. Rev.52, 595–638 (2000).
6. Lee M. Neurotransmitters and microglial-mediated neuroinflammation. Curr. Protein Pept. Sci.14, 21–32 (2013).
7. Szelényi J. Cytokines and the central nervous system. Brain. Res. Bull.54, 329–338 (2001).
8. Reyes-García M.G. & García-Tamayo F. A neurotransmitter system that regulates macrophage pro-inflammatory functions. J. Neuroimmunol.216, 20–31 (2009).
9. Ramberg V., Tracy L.M., Samuelsson M., Nilsson L.N. & Iverfeldt K. The CCAAT/enhancer binding protein (C/EBP) δ is differently regulated by fibrillar and oligomeric forms of the Alzheimer amyloid-β peptide. J. Neuroinflammation.8, 14 (2011).
10. Weisman D., Hakimian E. & Ho G.J. Interleukins, inflammation, and mechanisms of Alzheimer’s disease. Vitam. Horm.74, 505–530 (2006).
11. Maedler K., Dharmadhikari G., Schumann D.M. & Størling J. Interleukin-targeted therapy for metabolic syndrome and type 2 diabetes. Handb. Exp. Pharmacol.2011, 257–278 (2011).
12. Solomon S. et al. Sustained hippocampal IL-1β overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J. Clin. Invest.117, 1595–1604 (2007).
13. Parajuli B. et al. Oligomeric amyloid β induces IL-1β processing via production of ROS: implication in Alzheimer’s disease. Cell Death Dis.4, 975 (2013).
14. Luheshi N.M., McColl B.W. & Brough D. Nuclear retention of IL-1 alpha by necrotic cells: a mechanism to dampen sterile inflammation. Eur. J. Immunol.39, 2973–2980 (2009).
15. Schuitemaker A. et al. Inflammatory markers in AD and MCI patients with different biomarker profiles. Neurobiol. Aging30, 1885–1889 (2009).
16. Helmy A.A., Naseer M.M., Shafie S.E. & Nada M.A. Role of interleukin 6 and alpha-globulins in differentiating Alzheimer and vascular dementias. Neurodegener. Dis.9, 81–86 (2012).
17. Hampel H. et al. Pattern of interleukin-6 receptor complex immunoreactivity between cortical regions of rapid autopsy normal and Alzheimer’s disease brain. Eur. Arch. Psychiatry. Clin. Neurosci.255, 269–278 (2006).
18. Quintanilla R.A., Orellana D.I., González-Billault C. & Maccioni R.B. Interleukin-6 induces Alzheimertype phosphorylation of tau protein by deregulating the cdk5/p35 pathway. Exp. Cell Res.295, 245–257 (2004).
19. Kaplin A. et al. IL-6 release by LPS-stimulated peripheral blood mononuclear cells as a potential biomarker in Alzheimer’s disease. Int. Psychogeriatr.21, 413–414 (2009).
20. Alsadany M.A., Shehata H.H., Mohamad M.I. & Mahfouz R.G. Histone deacetylases enzyme, copper, and IL-8 levels in patients with Alzheimer’s disease. Am. J. Alzheimers. Dis. Other. Demen.28, 54–61 (2013).
21. Kim S.M. et al. Identification of peripheral inflammatory markers between normal control and Alzheimer’s disease. BMC Neurol.11, 51 (2011).
22. Franciosi S., Choi H.B., Kim S.U. & McLarnon J.G. IL-8 enhancement of amyloid-beta (Abeta 1-42)-induced expression and production of pro-inflammatory cytokines and COX-2 in cultured human microglia. J. Neuroimmunol.159, 66–74 (2005).
23. Cruikshank W.W., Kornfeld H. & Center D.M. Signaling and functional properties of interleukin-16. Int. Rev. Immunol.16, 523–540 (1998).
24. Di Rosa M. et al. Chitotriosidase and inflammatory mediator levels in Alzheimer’s disease and cerebrovascular dementia. Eur. J. Neurosci.23, 2648–2656 (2006).
25. Dinarello C.A. Interleukin-18. Methods19, 121–132 (1999).
26. Malaguarnera L., Motta M., Di Rosa M., Anzaldi M. & Malaguarnera M. Interleukin-18 and transforming growth factor-beta 1 plasma levels in Alzheimer’s disease and vascular dementia. Neuropathology26, 307–312 (2006).
27. Sutinen E.M., Pirttilä T., Anderson G., Salminen A. & Ojala J.O. Pro-inflammatory interleukin-18 increases Alzheimer’s disease-associated amyloid-β production in human neuron-like cells. J. Neuroinflammation9, 199 (2012).
28. Tarkowski E., Liljeroth A.M., Nilsson A., Minthon L. & Blennow K. Decreased levels of intrathecal interleukin 1 receptor antagonist in Alzheimer’s disease. Dement. Geriatr. Cogn. Disord.12, 314–317 (2001).
29. Kiyota T. et al. CNS expression of anti-inflammatory cytokine interleukin-4 attenuates Alzheimer’s diseaselike pathogenesis in APP+PS1 bigenic mice. FASEB J.24, 3093–3102 (2010).
30. Shimizu E., Kawahara K., Kajizono M., Sawada M. & Nakayama H. IL-4-induced selective clearance of oligomeric beta-amyloid peptide(1-42) by rat primary type 2 microglia. J. Immunol.181, 6503–6513 (2008).
31. Magaki S., Mueller C., Dickson C. & Kirsch W. Increased production of inflammatory cytokines in mild cognitive impairment. Exp. Gerontol.42, 233–240 (2007).
32. Wang T. et al. The efficacy of plasma biomarkers in early diagnosis of Alzheimer’s disease. Int. J. Geriatr. Psychiatry29, 713–719 (2014).
33. Angelopoulos P. et al. Cytokines in Alzheimer’s disease and vascular dementia. Int. J. Neurosci.118, 1659–1672 (2008).
34. Martinez-Nunez R.T., Louafi F. & Sanchez-Elsner T. The interleukin 13(IL-13) pathway in human macrophages is modulated by microRNA-155 via direct targeting of interleukin 13 receptor alpha1 (IL13Ralpha1). J. Biol. Chem.286, 1786–1794 (2011).
35. Szczepanik A.M., Funes S., Petko W. & Ringheim G.E. IL-4, IL-10 and IL-13 modulate A beta(1—42)- induced cytokine and chemokine production in primary murine microglia and a human monocyte cell line. J. Neuroimmunol.113, 49–62 (2001).
36. Taylor J.M. et al. Type-1 interferon signaling mediates neuro-inflammatory events in models of Alzheimer’s disease. Neurobiol. Aging35, 1012–1023 (2014).
37. Le Page C., Génin P., Baines M.G. & Hiscott J. Interferon activation and innate immunity. Rev. Immunogenet.2, 374–386 (2000).
38. Sas A.R., Bimonte-Nelson H., Smothers C.T., Woodward J. & Tyor, W.R. Interferon-alpha causes neuronal dysfunction in encephalitis. J. Neurosci.29, 3948–3955 (2009).
39. Chakrabarty P. et al. IFN-gamma promotes complement expression and attenuates amyloid plaque deposition in amyloid beta precursor protein transgenic mice. J. Immunol.184, 5333–5343 (2010).
40. Baron R. et al. IFN-gamma enhances neurogenesis in wild-type mice and in a mouse model of Alzheimer’s disease. FASEB J.22, 2843–2852 (2008).
41. Zheng M. et al. Intrahippocampal injection of Aβ1-42 inhibits neurogenesis and down-regulates IFN-γ and NF-kB expression in hippocampus of adult mouse brain. Amyloid20, 13–20 (2013).
42. Lynch M.A. The impact of neuroimmune changes on development of amyloid pathology; relevance to Alzheimer’s disease. Immunology141, 292–301 (2014).
43. Tobinick E. Tumour necrosis factor modulation for treatment of Alzheimer’s disease: rationale and current evidence. CNS Drugs23, 713–725 (2009).
44. Rojo L.E., Fernández J.A., Maccioni A.A., Jimenez J.M. & Maccioni R.B. Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer’s disease. Arch. Med. Res.39, 1–16 (2008).
45. Zhang J., Peng M. & Jia J. Plasma Amyloid-β Oligomers and Soluble Tumor Necrosis Factor Receptors as Potential Biomarkers of AD. Curr Alzheimer Res.11, 325–331 (2014).
46. Cheng X., Yang L., He P., Li R. & Shen Y. Differential Activation of Tumor Necrosis Factor Receptors Distinguishes between Brains from Alzheimer’s Disease and Non-Demented Patients. J. Alzheimers. Dis.19, 621–630 (2010).
47. Buchhave P. et al. Soluble TNF receptors are associated with Aβ metabolism and conversion to dementia in subjects with mild cognitive impairment. Neurobiol. Aging31, 1877–1884 (2010).
48. Tan Z.S. & Seshadri S. Inflammation in the Alzheimer’s disease cascade: culprit or innocent bystander? Alzheimers Res. Ther.2, 6 (2010).
49. Enciu A.M. & Popescu B.O. Is there a causal link between inflammation and dementia? Biomed. Res. Int.2013, 316495 (2013).
50. Lee Y.J. et al. Inflammation and Alzheimer’s disease. Arch. Pharm. Res.33, 1539–1556 (2010).